Global Newsroom

CSL continues to provide medicines to patients around the world.

MARBURG, Germany

- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness

• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.

• The more convalescent plasma the industry collects – and the more quickly it does so – directly influences the timeline to deliver a potential hyperimmune globulin for COVID-19.

• The clinical trial, sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in which the CoVIg-19 Plasma Alliance will participate is expected to begin soon.

Here is how CSL Behring is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

KING OF PRUSSIA, Pa.

• Five coagulation researchers named this year’s recipients
• Professor Heimburger Awards and ISTH Virtual Congress sponsorship showcase CSL Behring’s commitment to hematology research

KING OF PRUSSIA, Pa.

- Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia
- CSL Behring now evaluating 5 approaches to preventing and treating COVID-19

KING of PRUSSIA, Pa.

• Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose
• CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B

PHILADELPHIA

King of Prussia, Pa

Global bleeding disorders community will connect and discuss treatment advances June 14-19, 2020

HATTERSHEIM, Germany

Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation

KING OF PRUSSIA, Pa

• Builds on CSL Behring’s promise and commitment to the transplant community
• Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio

SEATTLE and KING of PRUSSIA, Pa.

Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA)

WALTHAM, Mass. and KING OF PRUSSIA, Penn.

Thermo Fisher Scientific Inc. and CSL Limited have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL’s broader manufacturing objectives.

Redmond, Wash., USA, and New York

“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies

Osaka, JAPAN, and King of Prussia, PA, USA

- Rapidly expanding support for the Alliance is increasing donations of convalescent plasma to begin clinical production, while NIH collaboration confirms clinical trial approach

- Alliance urges anyone who has recovered from COVID-19 to consider donating today

KING OF PRUSSIA, Pa.

Study examined the safety and tolerability of faster infusion rates and higher infusion volumes, as well as the feasibility of a new manual push administration method

King of Prussia, Pa. and Sioux Falls, S.D.

COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer

Osaka, JAPAN, and King of Prussia, PA, USA

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

Philadelphia, Pa

Universities awarded $250,000 research grants as part of the CSL Behring-Science Center Research Acceleration Initiative

KING OF PRUSSIA, Pa

CSL Behring advances Ig clinical trial program to address unmet need in treating serious autoimmune disease